期刊
PHARMACOLOGICAL RESEARCH
卷 63, 期 6, 页码 463-472出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2011.01.014
关键词
Endothelin; Endothelium; Cardiovascular diseases; Endothelin receptor antagonists
资金
- Ministerio de Ciencia e Innovacion [SAF2006-02410, SAF2009-09085, SAF2009-07520, CSD-2007-0020]
- Comunidad Autonoma de Madrid (CARDIOVREP Consortium)
- Sociedad Espanola de Nefrologia
- Fundacion Medica Mutua Madrilena
- Fundacion Renal Inigo Alvarez de Toledo (FRIAT)
- Fundacion Genoma Espana
- Ministerio de Ciencia e Innovacion
The endothelin (ET) system consists of three peptide ligands (ET-1, ET-2 and ET-3) and two G-protein-coupled receptors, ETA and ETB. In the cardiovascular system, ETs, particularly ET-1, are expressed in smooth muscle cells, cardiomyocytes, fibroblasts, and notably in vascular endothelial cells. Intense research over the last 10 years has changed the original view of ET-1 as mainly a vasoconstrictor regulating blood pressure, into a biological factor regulating processes such as vascular remodeling, angiogenesis or extracellular matrix synthesis. The advent of specific (and type-selective) ET receptor antagonists has greatly fostered our knowledge of the biological function of ET-1, and has offered a potential therapeutic approach for numerous diseases including hypertension, atherosclerosis or fibrosis. In this article, we review the regulation of the expression of vascular ET-1, as well as the contribution of ET-1 to endothelial, smooth muscle and fibroblast cell function, with particular interest in the role of ET-1 in the development of cardiovascular diseases. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据